Resulting from the MONARCH series of clinical trials, abemaciclib is approved as monotherapy and in combination with endocrine therapy (ET) for the treatment of patients with hormone receptor-positive (HR +), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [2]. Here, ERBB2 is linked to aneurysmal bone cyst.